Table 2 Extent of additional benefit and recommendation status for all withdrawn medicines
Medicine | Reason for ‘no additional benefit’ ratinga | Number of guidelines with positive recommendation (total number of guidelines reviewed) | |||
|---|---|---|---|---|---|
At time of benefit assessment | Additional guidelines June 2016 | ||||
Guidelines | Recommendationb | Guidelines | Recommendationb | ||
Aliskiren/ amlodipine | No appropriate data | 1 (4) | Medicine (aliskiren) | 1 (2) | Medicine (aliskiren) |
Bromfenac | No dossier submitted | 4 (7) | Class (NSAID) | 1 (2) | Class (NSAID) |
Canagliflozin | Insufficient clinical superiority | 1 (4) | Class (SGLT-2 inhibitors) | 3 (3) | Medicine (canagliflozin) |
Canagliflozin/ metformin | Insufficient clinical superiority | 1 (5) | Class (SGLT-2 inhibitors/metformin) | 3 (3) | Class (SGLT-2 inhibitors/metformin) |
Colestilan | Insufficient clinical superiority | 1 (1) | Class (phosphate binding agents) | 1 (1) | Class (phosphate binding agents) |
Gaxilose | No dossier submitted | n.a. | n.a. | n.a. | n.a. |
Insulin degludec | Insufficient clinical superiority | 7 (7) | Class (basal insulin analogues) | 3 (3) | Medicine (insulin degludec) |
Living larvae from Lucilia sericata | No dossier submitted | 1 (1) | Medicine (living larvae) | n.a. | n.a. |
Linaclotide | Insufficient clinical superiority | 0 (4) | n.a. | 1 (1) | Medicine (linaclotide) |
Linagliptin | Insufficient clinical superiority | 2 (3) | Class (DPP-4 inhibitors) | 3 (3) | Medicine (linagliptin) and class (DPP-4 inhibitors) |
Lixisenatide | Insufficient clinical superiority | 5 (5) | Class (GLP-1 agonists) | 3 (4) | Medicine (lixisenatide) and class (GLP-1 agonists) |
Lomitapide | Insufficient clinical superiority | 0 (2) | n.a. | 1 (1) | Medicine (lomitapide) |
Lurasidone | Insufficient clinical superiority | 4 (4) | Medicine (lurasidone) | 2 (2) | Class (second generation antipsychotic drugs) |
Microbial collagenase | Insufficient clinical superiority | n.a. | n.a. | n.a. | n.a. |
Mirabegron | Insufficient clinical superiority | 0 (6) | n.a. | 1 (1) | Medicine (mirabegron) |
Perampanel | No appropriate data | 0 (1) | n.a. | 0 (1) | n.a. |
Regorafenib | Insufficient clinical superiority | 0 (7) | n.a. | 3 (6) | Medicine (regorafenib) |
Retigabine | No appropriate data | 1 (1) | Medicine (retigabine) | 1 (1) | Medicine (retigabine) |
Sipuleucel-T | n.a. | 4 (11) | Medicine (sipuleucel-T) | 5 (9) | Medicine (sipuleucel-T) |
Tafluprost/timolol | Insufficient clinical superiority | 2 (2) | Class (preservative- free medicines) | n.a. | n.a. |
Vildagliptin | Insufficient clinical superiority | 5 (5) | Medicine (vildagliptin) | 4 (4) | Medicine (vildagliptin) and class (DPP-4 inhibitor) |
Vildagliptin/ metformin | Insufficient clinical superiority | 5 (5) | Medicine (vildagliptin/metformin) | 4 (4) | Class (DPP-4 inhibitors/metformin) |